anti-serpinB13 monoclonal antibody

Anti-serpinB13 monoclonal antibody (including the humanized clone hB29) is an investigational biologic developed by researchers at the University of Minnesota for the treatment of type 1 diabetes (T1D) and potentially other inflammatory conditions such as COVID-19. The antibody targets serpinB13 (headpin), an intracellular clade B serine protease inhibitor that endogenously inhibits cathepsin L (catL). By blocking serpinB13, the antibody restores cathepsin L activity, which subsequently cleaves the extracellular domain of the Notch1 receptor. This downregulation of Notch signaling promotes the neogenesis, proliferation, and survival of Ngn3-positive pancreatic endocrine progenitor cells, facilitating their conversion into insulin-producing beta cells. In preclinical models of autoimmune diabetes, anti-serpinB13 monoclonal antibody therapy, particularly in combination with anti-CD3 therapy, has demonstrated the ability to preserve beta-cell mass and delay or prevent disease progression.

Other names

humanized anti-serpinB13 monoclonal antibodyhumanized antibody to serpinB13